Crosstalk in Met receptor oncogenesis

Trends in Cell Biology

Volumn 19, Issue 10, 2009, Pages 542-551

  Lai, Andrea Z ^a,b   Abella, Jasmine V ^a,b   Park, Morag ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; NK 4; PROTEIN TYROSINE KINASE; RECEPTOR BLOCKING AGENT; SCATTER FACTOR RECEPTOR; SCATTER FACTOR RECEPTOR ANTAGONIST; TRASTUZUMAB; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CELL MIGRATION; CELL SURVIVAL; DRUG TARGETING; EPITHELIUM; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULAR INTERACTION; MULTIPLE CANCER; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STOMACH TUMOR;

ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 70349329537     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcb.2009.07.002     Document Type: Review

References (96)

1. Peschard P., and Park M. From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 26 (2007) 1276-1285
2. Gherardi E., et al. Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 4046-4051
3. Birchmeier C., et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4 (2003) 915-925
4. Vasyutina E., et al. CXCR4 and Gab1 cooperate to control the development of migrating muscle progenitor cells. Genes Dev 19 (2005) 2187-2198
5. Huh C.G., et al. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4477-4482
6. Borowiak M., et al. Met provides essential signals for liver regeneration. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10608-10613
7. Neuss S., et al. Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells 22 (2004) 405-414
8. Forte G., et al. Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Stem Cells 24 (2006) 23-33
9. Maroun C.R., et al. The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol 19 (1999) 1784-1799
10. Kong-Beltran M., et al. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 6 (2004) 75-84
11. Lock L.S., et al. Grb2-independent recruitment of Gab1 requires the C-terminal lobe and structural integrity of the Met receptor kinase domain. J Biol Chem 278 (2003) 30083-30090
12. Peschard P., and Park M. Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 3 (2003) 519-523
13. Paliouras G.N., et al. Pak4, a novel Gab1 binding partner, modulates cell migration and invasion by the Met receptor. Mol Cell Biol (2009). http://mcb.asm.org/cgi/content/abstract/MCB.01286-08v1 10.1128/MCB.01286-08
14. Lamorte L., et al. Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions. Mol Biol Cell 13 (2002) 1449-1461
15. Rodrigues S.P., et al. CrkI and CrkII function as key signaling integrators for migration and invasion of cancer cells. Mol Cancer Res 3 (2005) 183-194
16. Frigault M.M., et al. Gab2 requires membrane targeting and the Met binding motif to promote lamellipodia, cell scatter, and epithelial morphogenesis downstream from the Met receptor. J Cell Physiol 214 (2008) 694-705
17. Hammond D.E., et al. Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene 20 (2001) 2761-2770
18. Thien C.B., and Langdon W.Y. Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2 (2001) 294-307
19. Kozlov G., et al. Structural basis for UBA-mediated dimerization of c-Cbl ubiquitin ligase. J Biol Chem 282 (2007) 27547-27555
20. Abella J.V., et al. Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol 25 (2005) 9632-9645
21. Abella J.V., and Park M. Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am J Physiol Endocrinol Metab 296 (2009) E973-E984
22. Mak H.H., et al. Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway. Oncogene 26 (2007) 7213-7221
23. Onozato R., et al. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 4 (2009) 5-11
24. Kong-Beltran M., et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 66 (2006) 283-289
25. Sangwan V., et al. Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase. J Biol Chem 283 (2008) 34374-34383
26. Sangwan V., et al. Protein-tyrosine phosphatase 1B deficiency protects against Fas-induced hepatic failure. J Biol Chem 281 (2006) 221-228
27. Goldoni S., and Iozzo R.V. Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 123 (2008) 2473-2479
28. Hedman H., and Henriksson R. LRIG inhibitors of growth factor signalling - double-edged swords in human cancer?. Eur J Cancer 43 (2007) 676-682
29. Gur G., et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 23 (2004) 3270-3281
30. Laederich M.B., et al. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 279 (2004) 47050-47056
31. Goldoni S., et al. Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol 185 (2009) 743-754
32. Shattuck D.L. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol 27 (2007) 1934-1946
33. Wang R., et al. Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 8425-8430
34. Nakamura Y., et al. Constitutive activation of c-Met is correlated with c-Met overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines. Cancer Sci 99 (2008) 14-22
35. Liu Y., et al. Coordinate integrin and c-Met signaling regulate Wnt gene expression during epithelial morphogenesis. Development 136 (2009) 843-853
36. Trusolino L.A., et al. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 107 (2001) 643-654
37. Wilhelmsen K., et al. Multiple functions of the integrin alpha6beta4 in epidermal homeostasis and tumorigenesis. Mol Cell Biol 26 (2006) 2877-2886
38. Merdek K.D., et al. Intrinsic signaling functions of the beta4 integrin intracellular domain. J Biol Chem 282 (2007) 30322-30330
39. Chen S.Y., and Chen H.C. Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion. Mol Cell Biol 26 (2006) 5155-5167
40. Swiercz J.M., et al. ErbB-2 and met reciprocally regulate cellular signaling via plexin-B1. J Biol Chem 283 (2008) 1893-1901
41. Gherardi E., et al. The sema domain. Curr Opin Struct Biol 14 (2004) 669-678
42. Conrotto P., et al. Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 23 (2004) 5131-5137
43. Giordano S., et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 4 (2002) 720-724
44. Wielenga V.J., et al. Expression of c-Met and heparan-sulfate proteoglycan forms of CD44 in colorectal cancer. Am J Pathol 157 (2000) 1563-1573
45. Orian-Rousseau V., et al. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 16 (2002) 3074-3086
46. Orian-Rousseau V., et al. 1Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell 8 (2007) 76-83
47. Singleton P.A., et al. CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem 282 (2007) 30643-30657
48. Matzke A., et al. Haploinsufficiency of c-Met in cd44-/- mice identifies a collaboration of CD44 and c-Met in vivo. Mol Cell Biol 27 (2007) 8797-8806
49. Fischer O.M., et al. Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem 279 (2004) 28970-28978
50. Follenzi A., et al. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 19 (2000) 3041-3049
51. Ishibe S., et al. Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology. Development 136 (2009) 337-345
52. Popsueva A., et al. GDNF promotes tubulogenesis of GFRalpha1-expressing MDCK cells by Src-mediated phosphorylation of Met receptor tyrosine kinase. J Cell Biol 161 (2003) 119-129
53. Rodrigues G.A., et al. Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing. Mol Cell Biol 11 (1991) 2962-2970
54. Smolen G.A., et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 2316-2321
55. Engelman J.A., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007) 1039-1043
56. Okuda K., et al. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 99 (2008) 2280-2285
57. Cappuzzo F., et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 20 (2009) 298-304
58. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (2008) 1061-1068
59. Pennacchietti S., et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3 (2003) 347-361
60. Migliore C., et al. MicroRNAs impair MET-mediated invasive growth. Cancer Res 68 (2008) 10128-10136
61. He L., et al. A microRNA component of the p53 tumour suppressor network. Nature 447 (2007) 1130-1134
62. Rong S., et al. Met Proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. Cancer Res 55 (1995) 1963-1970
63. Lewis B.C., et al. The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol. Cell. Biol. 25 (2005) 1228-1237
64. Ma P.C., et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65 (2005) 1479-1488
65. Ma P.C., et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 47 (2008) 1025-1037
66. Lee C.C., and Yamada K.M. Identification of a novel type of alternative splicing of a tyrosine kinase receptor. Juxtamembrane deletion of the c-met protein kinase C serine phosphorylation regulatory site. J Biol Chem 269 (1994) 19457-19461
67. Gandino L., et al. Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. J Biol Chem 269 (1994) 1815-1820
68. Di Renzo M.F., et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19 (2000) 1547-1555
69. Lorenzato A., et al. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res 62 (2002) 7025-7030
70. Graveel C., et al. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17198-17203
71. Shattuck D.L., et al. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 68 (2008) 1471-1477
72. Nakajima M., et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85 (1999) 1894-1902
73. Jo M., et al. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 275 (2000) 8806-8811
74. Tang Z., et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 99 (2008) 911-922
75. Huang P.H., et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 12867-12872
76. Pillay, V. et al. (2009) The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 11, 448-58, 2 p following 458
77. Stommel J.M., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318 (2007) 287-290
78. Yano S., et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68 (2008) 9479-9487
79. Xu K.P., and Yu F.S. Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing. Invest Ophthalmol Vis Sci 48 (2007) 2242-2248
80. Bonine-Summers A.R., et al. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther 6 (2007) 561-570
81. Bachleitner-Hofmann T., et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther 7 (2008) 3499-3508
82. Khoury H., et al. HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol Biol Cell 16 (2005) 550-561
83. Nath D., et al. Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J Cell Sci 114 (2001) 1213-1220
84. Lindemann K., et al. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology 51 (2007) 54-62
85. Rikova K., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131 (2007) 1190-1203
86. Guo A., et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 692-697
87. Mueller K.L., et al. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res 68 (2008) 3314-3322
88. Reznik T.E., et al. Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res 6 (2008) 139-150
89. Merlin S., et al. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene. Cancer Sci 100 (2009) 633-638
90. Tulasne D., et al. Proapoptotic Function of the MET Tyrosine Kinase Receptor through Caspase Cleavage. Mol. Cell. Biol. 24 (2004) 10328-10339
91. Namiki Y., et al. Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer. Int J Cancer 118 (2006) 1545-1555
92. Knudsen B.S., and Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 18 (2008) 87-96
93. Hoffmann K.M., et al. Gastrointestinal hormones cause rapid c-Met receptor down-regulation by a novel mechanism involving clathrin-mediated endocytosis and a lysosome-dependent mechanism. J Biol Chem 281 (2006) 37705-37719
94. Conrotto P., et al. Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 105 (2005) 4321-4329
95. van der Voort R., et al. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J. Biol. Chem. 274 (1999) 6499-6506
96. Bean J., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 20932-20937